Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The first clinical experience with the new GORE® septal occluder (GSO)

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Fractional Flow Reserve Guided PCI in Patients With and Without Left Ventricular Hypertrophy: a DANAMI-3-PRIMULTI Sub-study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A novel supra-annular plane to predict TAVI prosthesis anchoring in raphe-type bicuspid aortic valve disease: the LIRA plane

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Myocardial damage after ST-segment elevation myocardial infarction by use of bivalirudin or heparin: a DANAMI-3 substudy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vascular function in adults with cyanotic congenital heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fractional Flow Reserve Guided PCI in Patients With and Without Left Ventricular Hypertrophy: a DANAMI-3-PRIMULTI Sub-study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Implications of hydrodynamic testing to guide sizing of self-expanding transcatheter heart valves for valve-in-valve procedures

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Aims: A new GORE® septal occluder (GSO) was granted CE mark in Europe in June 2011 for the treatment of patent foramen ovale and atrial septal defect. Major changes have been made to the device and delivery system compared to the HELEX® device. The new delivery system has simplified the implantation procedure and the retrievability of the device after deployment if needed. The design of the GSO has improved the device apposition ability and tissue response whilst keeping its atraumatic design, low septal profile with minimal septal distortion and long-term biocompatibility. The first three clinical cases of GSO use in the world are briefly described and the immediate and short-term outcome of the first eleven patients who underwent PFO or ASD closure using GSO in our centre are reported. Methods and results: The mean age of the eleven patients was 53±9 years and six of them were women. Ten of these patients had patent foramen ovale and one had secundum atrial septal defect. In all the cases, the GSO devices were successfully deployed in the first attempt without any complication. Only one patient had a minor residual shunt detected immediately after the device deployment. All the patients were re-assessed 70±33 days later and no residual shunt was detected in any of them. One of the patients had an episode of paroxysmal atrial fibrillation. There was no device fracture found in the six patients who also had a fluoroscopic examination during follow-up. Conclusions: Our initial experience with GSO shows promise in handling and occlusion rate. Larger-scale and longer-term outcome on the performance of GSO is required to ensure safety and efficacy.
Original languageEnglish
JournalEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Volume9
Issue number8
Pages (from-to)959-63
Number of pages5
ISSN1774-024X
DOIs
Publication statusPublished - 23 Dec 2013

ID: 42923938